The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells

Cancer Letters

Volumn 321, Issue 2, 2012, Pages 187-194

  Tavolari, Simona ^a   Munarini, Alessandra ^a   Storci, Gianluca ^a,b   Laufer, Stefan ^c   Chieco, Pasquale ^a   Guarnieri, Tiziana ^a,b,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Biostructures and Biosystems National Institute (INBB)   (Italy)

Author keywords

Apoptosis; Colon cancer; Epidermal growth factor receptor; Licofelone; Membrane fluidity

Indexed keywords

CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LICOFELONE; MITOGEN ACTIVATED PROTEIN KINASE; MONOUNSATURATED FATTY ACID; P44 42 MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE FLUIDITY; COLON CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; COLONIC NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MEMBRANE FLUIDITY; MITOGEN-ACTIVATED PROTEIN KINASES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84860915193     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.003     Document Type: Article

References (44)

1. Herendeen J.M., Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann. Pharmacother. 2003, 37:1664-1674.
2. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Sci. 2008, 11:81s-110s.
3. Lichtenberger L.M., Wang Z.M., Romero J.J., Ulloa C., Perez J.C., Giraud M.N., Barreto J.C. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med. 1995, 1:154-158.
4. Sousa C., Nunes C., Lúcio M., Ferreira H., Lima J.L., Tavares J., Cordeiro-da-Silva A., Reis S. Effect of non steroidal anti-inflammatory drugs on the cellular membrane fluidity. J. Pharm. Sci. 2008, 97:3195-3206.
5. Moreno M.M., Garidel P., Suwalsky M., Howe J., Brandenburg K. The membrane-activity of Ibuprofen, Diclofenac, and Naproxen: a physico-chemical study with lecithin phospholipids. Biochim. Biophys. Acta 2009, 1788:1296-1303.
6. Moreno M.M., Garidel P., Suwalsky M., Howe J., Brandenburg K. Structural effects in vitro of the anti-inflammatory drug diclofenac on human erythrocytes and molecular models of cell membranes. Biophys. Chem. 2009, 141:34-40.
7. Escribá P.V., González-Ros J.M., Goñi F.M., Kinnunen P.K., Vigh L., Sánchez-Magraner L., Fernández A.M., Busquets X., Horváth I., Barceló-Coblijn G. Membranes: a meeting point for lipids, proteins and therapies. J. Cell. Mol. Med. 2008, 12:829-875.
8. Tavolari S., Bonafè M., Marini M., Ferreri C., Bartolini G., Brighenti E., Manara S., Tomasi V., Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008, 29:371-380.
9. Zhang J., Roberts T.M., Shivdasani R.A. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 2011, 141:50-61.
10. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2009, 26:3291-3310.
11. Merrill A.R., Aubry H., Proulx P., Szabo A.G. Relation between calcium uptake and fluidity of brush-border membranes incubated with fatty acid and methyl-oleate. Biochim. Biophys. Acta 1987, 896:89-95.
12. Belluzzi A., Brignola C., Campieri M., Pera A., Boschi S., Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. 1996, 334:1557-1560.
13. Hofstetter H.H., Sen N., Holman R.T. Characterization of unsaturated fatty acids by gas-liquid chromatography. J. Am. Oil. Chem. Soc. 1965, 42:537-540.
14. Zlatkis A.A., Zack B., Boyle A.J. A new method for direct determination of serum cholesterol. J. Lab. Clin. Med. 1953, 41:486-492.
15. King I.C., Catino J.J. Nonradioactive ligand binding assay for epidermal growth factor receptor. Anal. Biochem. 1990, 188:97-100.
16. Hac-Wydro K., Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem. Phys. Lipids 2007, 150:66-81.
17. Leekumjorn S., Cho H.J., Wu Y., Wright N.T., Sum A.K., Chan C. The role of fatty acid unsaturation in minimizing biophysical changes on the structure and local effects of bilayer membranes. Biochim. Biophys. Acta 2009, 1788:1508-1516.
18. Repáková J., Holopainen J.M., Karttunen M., Vattulainen I. Influence of pyrene-labeling on fluid lipid membranes. J. Phys. Chem. B 2006, 110:15403-15410.
19. Modjtahedi H., Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009, 20:851-855.
20. Ge G., Wu J., Lin Q. Effect of membrane fluidity on tyrosine kinase activity of reconstituted epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 2001, 282:511-514.
21. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
22. Cunningham M.P., Thomas H., Fan Z., Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor Gefitinib. Cancer Res. 2006, 66:7708-7715.
23. Vacaresse N., Lajoie-Mazenc I., Augé N., Suc I., Frisach M.F., Salvayre R., Nègre-Salvayre A. Activation of epithelial growth factor receptor pathway by unsaturated fatty acids. Circ. Res. 1999, 85:892-899.
24. Steelman L.S., Abrams S.L., Shelton J.G., Chappell W.H., Bäsecke J., Stivala F., Donia M., Nicoletti F., Libra M., Martelli A.M., McCubrey J.A. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010, 9:1629-1638.
25. Vigh L., Escribá P.V., Sonnleitner A., Sonnleitner M., Piotto S., Maresca B., Horváth L., Harwood J.L. The significance of lipid composition for membrane activity: new concepts and ways of assessing function. Prog. Lipid Res. 2005, 44:303-344.
26. Meng X., Riordan N.H., Riordan H.D., Mikirova N., Jackson J., González M.J., Miranda-Massari J.R., Mora E., Trinidad Castillo W. Cell membrane fatty acid composition differs between normal and malignant cell lines. PR Health. Sci. J. 2004, 23:103-106.
27. Cooper R.A. Abnormalities of cell-membrane fluidity in the pathogenesis of disease. N. Engl. J. Med. 1977, 297:371-377.
28. Baritaki S., Apostolakis S., Kanellou P., Dimanche-Boitrel M.T., Spandidos D.A., Bonavida B. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv. Cancer Res. 2007, 98(2007):49-90.
29. Giraud M.N., Motta C., Romero J.J., Bommelaer G., Lichtenberger L.M. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem. Pharmacol. 1999, 57:247-254.
30. Lichtenberger L.M., Zhou Y., Dial E.J., Raphael R.M. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J. Pharm. Pharmacol. 2006, 58:1421-1428.
31. Kelly S.B., Miller J., Wood C.B., Williamson R.C., Habib N.A. Erythrocyte stearic acid desaturation in patients with colorectal carcinoma. Dis. Colon Rectum. 1990, 33:1026-1030.
32. King I.C., Catino J.J. Nonradioactive ligand binding assay for epidermal growth factor receptor. Anal. Biochem. 1990, 188:97-100.
33. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000, 60(Suppl. 1):25-32. 41-42.
34. Moolenaar W.H., Bierman A.J., Tilly B.C., Verlaan I., Defize L.H., Honegger A.M., Ullrich A., Schlessinger J. A point mutation at the ATP-binding site of the EGF-receptor abolishes signal transduction. EMBO J. 1988, 7:707-710.
35. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6:1024-1028.
36. Lippman S.M., Gibson N., Subbaramaiah K., Dannenberg A.J. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2. Clin. Cancer Res. 2005, 11:6097-6099.
37. Buchanan F.G., Holla V., Katkuri S., Matta P., DuBois R.N. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67:9380-9388.
38. Pike J.L. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim. Biophys. Acta 2005, 1746:260-273.
39. Bethani I., Skånland S.S., Dikic I., Acker-Palmer A. Spatial organization of transmembrane receptor signalling. EMBO J. 2010, 29:2677-2688.
40. Brown D.A., London D. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 2000, 275:17221-17224.
41. Pike J.L. Lipid rafts: bringing order or caos. J. Lipid Res. 2003, 44:655-667.
42. Pike J.L., Casey L. Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 2002, 41:10315-10322.
43. Bias P., Buchner A., Klesser B., Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am. J. Gastroenterol. 2004, 99:611-618.
44. Moreau M., Daminet S., Martel-Pelletier J., Fernandes J., Pelletier J.P. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J. Vet. Pharmacol. Ther. 2005, 28:81-86.